|
Patent landscape, scope, and claims: |
US Patent 8,357,713 scope and claims for gout and hyperuricemia therapies: what’s protected, how broad it is, and who competes
Executive summary: US 8,357,713 protects a pharmaceutical composition containing a specific compound defined by Formula (IV) (and pharmaceutically acceptable salt/ester/tautomer forms) plus downstream medical-use claims for reducing serum uric acid, treating gout, and treating hyperuricemia. The patent also includes combination-product claims where the Formula (IV) composition is paired with a second gout/hyperuricemia agent, explicitly covering URAT1 inhibitors and xanthine oxidase/xanthine oxidoreductase pathway inhibitors, with examples including allopurinol and febuxostat. The practical enforceable “center of gravity” is (i) the active compound identity defined by Formula (IV), (ii) whether generic or branded products are formulated as tablets/capsules and coated tablets, and (iii) whether the product includes a second agent meeting the claim-defined classes.
What is US 8,357,713 and what does it claim for gout and hyperuricemia?
Core claim theme: a composition containing a Formula (IV) compound, with method-of-use and combination claim coverage tied to clinical indications in humans.
Claim 1: what composition is protected
Claim 1 is a pharmaceutical composition comprising:
- “a compound of formula (IV)” (structure defined in the patent specification), or
- a pharmaceutically acceptable salt, ester, or tautomer of that compound.
Claim 1 coverage in practice
- Active-ingredient scope is defined structurally by Formula (IV).
- Form scope includes salt/ester/tautomer variants that fall within “pharmaceutically acceptable” definitions.
- The claim is drafted as a composition claim with no explicit dosage form limitation in Claim 1 itself (dosage forms appear in dependent claims).
Claims 2–4: method-of-use coverage
- Claim 2: method for reducing serum uric acid levels by administering the composition of Claim 1.
- Claim 3: method of treating gout in a human.
- Claim 4: method of treating hyperuricemia in a human.
These are classic indication-based method claims tethered to the same protected composition.
Claims 5–8: combination therapy
- Claim 5: Claim 1 composition + “a second agent effective for treatment of gout.”
- Claim 6: Claim 5 specifies the second agent is a:
- URAT1 inhibitor, or
- xanthine oxidase inhibitor, or
- xanthine dehydrogenase, or
- xanthine oxidoreductase inhibitor, or
- combination(s) of the above.
- Claim 7: second agent is allopurinol.
- Claim 8: second agent is febuxostat.
This creates a clear combination infringement map for dual or add-on regimens using urate-lowering agents from the specified pharmacologic classes.
Claims 9–12: dosage form and carrier
- Claim 9: composition further comprises a pharmaceutically acceptable carrier, diluent, or binder (broad excipient language).
- Claim 10: composition is a tablet or capsule.
- Claim 11: composition is a tablet.
- Claim 12: composition is a coated tablet.
These dependent claims narrow to common oral solid forms.
How broad is Claim 1’s “compound of formula (IV)” scope?
Featured snippet answer: Claim 1 is broad at the “formula-defined active ingredient” level, with additional breadth from allowing salts/esters/tautomers, but narrow in that it requires the active to match Formula (IV) as construed from the patent’s structural definition.
What Claim 1 likely captures
- The exact Formula (IV) compound.
- Any salt forms that are “pharmaceutically acceptable” (typically salts with standard counterions used in the art and recognized by the patent).
- Any tautomers and potentially esters where the patent treats them as pharmaceutically acceptable.
What Claim 1 does not explicitly cover
- No explicit coverage is stated in the claims you provided for:
- prodrugs that are outside the literal formula/tautomer/salt definitions,
- metabolites not encompassed as tautomers or salts,
- structural variants not falling within Formula (IV).
Bottom line for freedom-to-operate: validity and infringement hinge on whether the accused active matches Formula (IV) (or a salt/ester/tautomer that is within the “pharmaceutically acceptable” language).
What patentable “indication” does US 8,357,713 cover: serum uric acid, gout, or hyperuricemia?
Featured snippet answer: It covers three human treatment paradigms using the protected Formula (IV) composition: serum uric-acid reduction, gout treatment, and hyperuricemia treatment.
Infringement sensitivity by method claim
Method claims are typically enforced against:
- prescribing and/or dispensing of the patented composition for the claimed indication (depending on jurisdiction and theory), and
- potentially labeling, instructions, and marketing that tie administration to the claimed use.
Key point: all three method claims are tethered to Claim 1. If an accused product does not contain the Formula (IV) compound, the method claims generally fall away.
Does US 8,357,713 cover combination products with URAT1 inhibitors and xanthine oxidase inhibitors?
Featured snippet answer: Yes. Dependent Claims 5–8 explicitly cover combination compositions that include Claim 1 plus a second gout/hyperuricemia agent from URAT1 or xanthine-oxidation pathway classes, including allopurinol and febuxostat.
Combination claim structure
- Claim 5: any second agent “effective for treatment of gout” (functional breadth).
- Claim 6: second agent must belong to defined classes (URAT1 inhibitors or xanthine oxidase/dehydrogenase/oxidoreductase inhibitors).
- Claims 7–8: examples narrow to two widely used xanthine inhibitors.
Practical competitive implications
- If a competitor launches a fixed-dose combo including the Formula (IV) composition plus:
- allopurinol or febuxostat, then Claims 5–8 are directly implicated.
- If the competitor launches a combo using a different xanthine inhibitor than allopurinol/febuxostat but within the Claim 6 class (xanthine oxidase/oxidoreductase pathway inhibitor), then Claim 6 and Claim 5 are still relevant.
Open design-around avenue
If competitors avoid:
- combination packaging and
- the presence of a second agent within the Claim 6 class,
then they can attempt to evade the combination claim set, while still facing Claim 1 and method-of-use claims for monotherapy.
What dosage forms are covered by US 8,357,713 (tablets, capsules, coated tablets)?
Featured snippet answer: Dependent claims cover oral dosage forms: tablet or capsule, with further narrowing to tablet and coated tablet.
How this affects product design
- If the Formula (IV) active is formulated as an oral solid dosage form, the dependent claims create additional claim coverage for specific presentation:
- tablets and coated tablets in particular.
- If the same active is sold as a route or dosage form not encompassed by Claims 10–12, Claim 1 still remains available. The dependent claims mainly add fallback positions.
What are the likely “active-ingredient risk zones” for generic or follow-on entrants?
Featured snippet answer: Risk zones are any products that (i) use the Formula (IV) compound (or a qualifying salt/ester/tautomer) in the claimed composition, and/or (ii) administer it for serum uric acid reduction, gout, or hyperuricemia, and/or (iii) sell it as a combo with URAT1 and/or xanthine pathway inhibitors.
Monotherapy scenario
- A generic that matches Formula (IV) and is used for gout/hyperuricemia is within Claims 1–4.
Combination scenario
- A generic or branded combo that pairs the Formula (IV) compound with allopurinol or febuxostat is squarely within Claims 5–8.
- Even if not allopurinol/febuxostat, combos with URAT1 inhibitors or xanthine oxidase/dehydrogenase/oxidoreductase inhibitors are within Claim 6.
What does the patent landscape around US 8,357,713 typically look like for urate-lowering drugs?
Featured snippet answer: The landscape for gout/hyperuricemia compositions usually clusters around three layers: (1) active-ingredient structural patents, (2) formulation/dosage patents, and (3) method-of-use patents for serum urate reduction and specific indications. This patent is primarily at layers (1) and (2)/(3) via Claim 1 and indication/combination claims.
Competing pharmacologic classes (relevant to Claim 6)
- URAT1 inhibitors (urate transport)
- Xanthine oxidase/dehydrogenase/oxidoreductase pathway inhibitors (urate production)
How this interacts with typical competitor patent estates
- If competitors own patents on their specific actives (URAT1 inhibitors, xanthine inhibitors) they may not avoid US 8,357,713 unless they avoid Formula (IV) entirely.
- If competitors develop fixed-dose combos, they may collide with Claim 5–8 even if their monotherapy active is different, because the claim is active-defined for the Formula (IV) component and class-defined for the second component.
When does US 8,357,713 lose exclusivity (generic entry timing and regulatory leverage)?
No timeline can be provided from the claim text alone. A complete “expiration/exclusivity calendar” requires the patent’s issue date, filing history, term adjustments, and any FDA regulatory exclusivities or patent-term extensions tied to the specific NDA/ANDA.
What FDA regulatory status and Orange Book listing issues matter for enforcing US 8,357,713?
No FDA listing data can be derived from the claims you provided. Orange Book listing presence, listed patents (and claim numbers), and the applicable NDA/ANDA and reference drug are determinative for:
- Paragraph IV strategy,
- trigger events for litigation,
- and whether the enforceable scope aligns with the listed claim(s).
How strong is the patent estate for enforcement based on the claim set alone?
Featured snippet answer: Strength is anchored by (i) a formula-defined composition claim (Claim 1) and (ii) multiple dependent medical-use claims (Claims 2–4) plus (iii) combination claim pathways (Claims 5–8) that map to common gout standard-of-care agents.
Strength drivers
- Structural limitation in Claim 1 is the likely focal point for validity and infringement. If the Formula (IV) compound is commercially used, enforceability is practical.
- Multiple method claims share the same dependency base. Even if one method theory narrows in litigation, other method claims still exist (serum urate reduction, gout, hyperuricemia).
- Combination claims explicitly cover:
- URAT1 inhibitor class,
- xanthine pathway inhibitor class,
- and named exemplars allopurinol and febuxostat.
Potential weakening factors (claim-construction dependent)
- If “compound of formula (IV)” is construed narrowly, design-arounds via salt/tautomer selection may not help because salts/tautomers are already included.
- If the second agent in combination products is outside Claim 6 classes or not “effective for treatment of gout” as construed, Claim 5–8 may narrow.
What patent litigation issues are most likely to arise for US 8,357,713?
No docket or litigation history can be derived from the claims you supplied. However, claim set structure points to standard dispute lanes:
Claim construction
- What compounds satisfy “formula (IV)” definition, including salt/ester/tautomer boundaries.
- Whether an accused product’s active matches the Formula (IV) structure and qualifies as a “pharmaceutically acceptable” salt/ester/tautomer.
Infringement theories
- Direct composition infringement for products containing the Formula (IV) compound.
- Indication-based method infringement depending on applicable enforcement mechanism.
- Combination infringement if the product includes a second agent meeting Claim 6 classes and is used for gout.
Validity attack themes
- Obviousness and anticipation tied to how Formula (IV) was disclosed or rendered obvious at filing.
- Enablement and written description are common for structural formula families.
- For combination claims: whether prior art discloses the combination and whether it would have been obvious.
Key Takeaways
- US 8,357,713 Claim 1 protects a pharmaceutical composition containing a Formula (IV) compound (plus pharmaceutically acceptable salts/esters/tautomers).
- Claims 2–4 extend protection to human use for reducing serum uric acid, treating gout, and treating hyperuricemia, all tied to the Claim 1 composition.
- Claims 5–8 create combination-product coverage: pairing the Formula (IV) composition with a second gout-effective agent, including URAT1 inhibitors and xanthine oxidation pathway inhibitors, with explicit exemplars allopurinol and febuxostat.
- Claims 10–12 add dependent coverage for tablet/capsule presentations, including coated tablets.
- For competitive strategy, the decisive question is whether a competitor’s product contains the Formula (IV) active and whether launch strategy involves indication use and/or combo regimens that fall within the Claim 5–8 classes.
FAQs
-
Can a competitor avoid US 8,357,713 by selling a different salt of the Formula (IV) compound?
The patent includes “pharmaceutically acceptable salt, ester, or tautomer,” so salt-only design-arounds are unlikely to remove Claim 1 coverage if the underlying compound remains within Formula (IV).
-
Does US 8,357,713 require a specific dose or dosing regimen?
The provided claims do not impose dose or regimen limitations. Dependent claims focus more on composition components and dosage form types (tablet/capsule/coated tablet).
-
How do the method claims relate to the composition claim?
Claims 2–4 depend on administering the Claim 1 composition. If a product does not include the Formula (IV) compound (or qualifying salt/ester/tautomer), the method claims generally lose a common dependency base.
-
What combinations are explicitly covered besides URAT1 inhibitors?
The patent explicitly covers combinations using allopurinol and febuxostat and class coverage for xanthine oxidase/dehydrogenase/oxidoreductase inhibitors.
-
If a competitor launches a gout therapy without a second agent, is it still at risk?
Yes. Even without combination therapy, Claims 1–4 can apply to monotherapy products that include the Formula (IV) compound and are used to reduce serum uric acid, treat gout, or treat hyperuricemia.
References
No citable external sources were provided in the prompt, and no patent bibliographic details (issue date, inventors, specification text for Formula IV, or USPTO/Orange Book listing) were included.
More… ↓
⤷ Start Trial
|
